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Abstract 
Regulated upon activation, normal T-cell expressed and secreted (RANTES) is one of the 
most extensively studied C-C chemokines in allergic inflammation. A growing body of evi-
dence suggests that many cell types present in asthmatic airways have the capacity to gen-
erate RANTES, which directly supported the potential role of RANTES in asthma. A number 
of studies have evaluated the functional polymorphism -28C/G in the RANTES promoter re-
gion, which had been found to affect the transcription of the RANTES gene, in relation to 
asthma susceptibility. However, the results remain conflicting rather than conclusive. This 
meta-analysis on 1894 asthma cases and 1766 controls for -28C/G from 9 published 
case-control studies showed that the variant allele -28G was associated with significantly 
increased risk of asthma (GG+CG vs CC: OR=1.24, 95%CI=1.08-1.41) without any be-
tween-study heterogeneity. 
In the stratified analysis by asthma type, age and ethnicity, we found that the increased 
asthma risk associated with -28G/C polymorphism was more evident in children (OR=1.24, 
95%CI=1.06-1.45), Asian group (OR=1.27, 95%CI=1.04-1.56) and African group (OR=1.72, 
95%CI=1.07-2.78). These results suggest that RANTES -28G/C polymorphism may contrib-
ute to asthma development, especially in children and in Asian population. Additional 
well-designed large studies were required for the validation of this association. 
Key words: RANTES, polymorphism, susceptibility, asthma, meta-analysis 
Introduction 
Asthma is a chronic inflammatory disorder of 
the airways and is characterized by variable airflow 
obstruction and bronchial hyper responsiveness 
(BHR) [1].  The prevalence and severity of asthma 
have been increasing in many countries, the trends 
being most pronounced for children and adolescents 
[2]. The pathogenesis and etiology of asthma is very 
complex and not fully understood, although an in-
teraction of multiple genetic loci and a variety of en-
vironmental factors have been suggested as impor-
tant determinants of this disease [3,4]. It was reported 
that asthma is a disease with a strong genetic predis-
position, and the recent increase in asthma cases 
seems to be triggered by increases in environmental Int. J. Med. Sci. 2010, 7 
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exposures in previously unaffected but genetically 
susceptible individuals [5]. However, different ge-
netic background individuals in the same environ-
mental exposures showed different susceptibility to 
asthma, which indicated that genetic factors may play 
an important role in the pathogenesis of asthma.   
Regulated upon activation, normal T-cell ex-
pressed and secreted (RANTES), which generated by 
T lymphocyte, is one of the most extensively studied 
C-C chemokines in allergic inflammation[6]. RANTES 
is likely to be important in airway inflammation be-
cause blocking antibodies to RANTES inhibit airway 
inflammation in a murine model of allergic airway 
disease [7]. A growing body of evidence suggests that 
many cell types present in asthmatic airways, such as 
T cells, platelets, macrophages, endothelial cells, fi-
broblasts, epithelial cells, and mast cells, have the ca-
pacity to generate RANTES [8], which directly sup-
ported the potential role of RANTES in asthma. 
The gene encoding RANTES is located on chro-
mosome 17q11.2-q12 [9] that has been shown to be in 
linkage with asthma in several studies [10,11]. The 
-28C/G polymorphism in the RANTES promoter re-
gion had been found to affect the transcription of the 
RANTES gene. In human cell lines, the -28G was 
shown to increase promoter activity of RANTES in 
comparison with the more frequent -28C, suggesting 
that the polymorphism can increase RANTES expres-
sion in the human body [12]. Therefore, it’s reason-
able to hypothesize that the RANTES -28C/G poly-
morphism may functionally relate to the risk of 
asthma. 
A number of molecular epidemiological studies 
have been conducted to examine the association be-
tween  RANTES -28C/G polymorphism and asthma 
susceptibility [1,13-20], but the results remain incon-
sistent. To estimate the overall risk of RANTES 
-28C/G associated with asthma risk and to quantify 
the potential between-study heterogeneity, we con-
ducted a meta-analysis on 9 published case-control 
studies with 1894 asthma cases and 1766 controls for 
-28C/G. 
Materials and Methods 
Identification and Eligibility of Relevant 
Studies. Eligible studies were identified by searching 
the electronic literature PubMed and EMBASE for 
relevant reports (last search update February 2009, 
using the search terms “RANTES”, “polymorphisms” 
and “asthma”; “CCL5”, “polymorphisms” and 
“asthma”). Additional studies were identified by 
hands-on searches from references of original studies 
or review articles on this topic. Searching was per-
formed in duplicate by two independent reviewers 
(Q.F. and F.W.). Results were limited to English lan-
guage papers and Chinese language papers.   
Inclusion criteria. We attempted to include all 
the case-control studies published to date on the as-
sociation between RANTES  -28C/G polymorphism 
and asthma risk. Human studies, regardless of sam-
ple size, were included if they met the following cri-
teria: 
(1) RANTES polymorphism at -28C/G were de-
termined. 
(2) Studies were case-control design (retrospec-
tive or nested case-control).   
(3) Each genotype frequency was reported, and 
there was sufficient information for extraction of 
data. 
(4) If studies had partly overlapped subjects, 
only the one with a larger and/or latest sample size 
was selected for the analysis. 
Data Extraction. Two reviewers (Q.F. and F.W.) 
independently extracted data and reached a consen-
sus on all of the items. Data extracted from these arti-
cles included the first author’s name, year of publica-
tion, country of origin, ethnicity, type of asthma, 
number of cases and controls, and the minor allele fre-
quency in controls.   
Meta-Analysis. The risk of asthma associated 
with -28C/G RANTES was estimated for each study 
by odds ratio (OR) with 95% confidence intervals 
(95%CI). For all studies, we evaluated the risk of the 
variant genotypes (GG/CG), compared with the 
wild-type genotype (CC). Then we calculated the ORs 
of the polymorphism (GG+CG versus CC, and GG 
versus CG+CC), using both dominant and recessive 
genetic models of the variant G allele. In addition, we 
conducted stratification analysis by asthma types, age 
and ethnicity. As a result, 2 case-control studies  of 
asthma type (777 cases and 495 controls); 9 
case-control studies of age (1894 cases and 1766 con-
trols) and 9 case-control studies of ethnicity (1894 
cases and 1766 controls) were available for this 
meta-analysis. The χ2-based Q statistic test was used 
for the assessment of heterogeneity, and it was con-
sidered significant for P < 0.01. We used the 
fixed-effects model and the random-effects model 
based on the Mantel-Haenszel method and the Der-
Simonian and Laird method, respectively, to combine 
values from each of the studies. When the effects 
were assumed to be homogenous, the fixed-effects 
model was then used; otherwise, the random-effects 
model was more appropriate. We also computed the 
power of the selected studies by using the 
DSTPLAN4.2 software, in order to assess the prob-
ability of detecting an association between RANTES 
-28C/G polymorphism and asthma at the 0.05 level of Int. J. Med. Sci. 2010, 7 
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significance, assuming a genotypic risk of 2.0 and 1.5. 
The Egger’s test and inverted funnel plots were util-
ized to provide diagnosis of publication bias (Linear 
regression analysis, ref. [21]). All analysis was done 
by using the Statistical Analysis System software 
(v.9.1.3, SAS Institute, Cary, NC) and Review Manage 
(v.4.2). All the P values were two-sided. 
Results 
The selected study characteristics are listed in 
Table 1. All studies indicated that the distributions of 
the -28C/G polymorphism’s genotypes in the con-
trols were both consistent with Hardy-Weinberg 
equilibrium except for two studies [18,19]. The minor 
G allele frequency (MAF) was 0.14 for Asian studies, 
0.06 for African, while around 0.03 for Caucasian, 
respectively. 
Variant genotypes of RANTES -28C/G poly-
morphisms were associated with an increased asthma 
risk in different genetic models. As shown in Table 2, 
both the variant homozygote (-28GG) and heterozy-
gote (-28CG) were associated with a significantly in-
creased risk of asthma (GG versus CC: OR=1.98, 
95%CI=1.24-3.16; P = 0.29 for heterogeneity test; CG 
versus CC: OR=1.25, 95%CI=1.04-1.50; P = 0.60 for 
heterogeneity test), compared with wild-type homo-
zygote (-28CC). Significant main effects were also 
observed in the dominant genetic model (GG+CG 
versus CC: OR=1.24, 95%CI=1.08-1.41; P = 0.47 for 
heterogeneity test; Table 2 and Figure 1).   
We further performed stratified analysis ac-
cording to asthma type (atopic asthma and 
non-atopic asthma), age (children and adult) and eth-
nicity (Asian and Caucasian and African ethnicity), 
and the estimate results were presented in Table 3. As 
shown in the table, we found that the increased 
asthma risk associated with -28G/C polymorphism 
was more evident in children (OR=1.24, 
95%CI=1.06-1.45, P=0.39 for heterogeneity test), Asian 
group (OR=1.27, 95%CI=1.04-1.56, P=0.48 for hetero-
geneity test) and African group (OR=1.72, 
95%CI=1.07-2.78, P=0.23 for heterogeneity test). 
We used Funnel plot and Egger’s test to access 
the publication bias of literatures. As shown in Fig. 2, 
the shape of the funnel plots seemed symmetrical in 
the dominant genetic model for the -28C/G, suggest-
ing that there was no publication bias. Egger’s test 
was used to provide statistical evidence. As a result, 
no publication bias was observed for -28C/G (t=2.30, 
P = 0.92).   
 
 
 
Table 1. Characteristics of published studies included in the meta-analysis. 
Power (%) †  Author[ref*) Year  Origin 
(Ethnicity) 
Asthma group 
(CC/CG/GG) 
Control group 
(CC/CG/GG) 
HWE MAF   
in controls  OR>1.5 OR>2.0 
Szalai C[13]& 2001  Hungary 
( Caucasian) 
144/16/0 284/19/0 0.573  0.03  11.9  29.7 
Hizawa N[14]  2002  Japan 
( Asian) 
216/70/12 243/62/6  0.387  0.12  41.7 88.2 
Yao TC[15]  2003  China(Taiwan) 
( Asian) 
134/39/9 83/23/1  0.666  0.12  21.3  55.3 
Wang LJ[16]  2004  China 
( Asian) 
65/31/4 72/17/1 0.998  0.11  15.5  39.7 
Huang JL [17]  2005  China(Taiwan) 
( Asian) 
189/53/9 83/23/1  0.666  0.12  23.3  59.8 
Moissidis I[18]  2005  United States 
( African-American) 
59/2/0 129/0/0  0.000  0.00  NA# NA# 
Lachheb J[19]  2007  Tunisia 
( African) 
163/35/12 190/29/5  0.005  0.09  25.8 65.9 
Muro M[20]  2008  Spain 
(Caucasian) 
289/17/0 228/14/0 0.643  0.03  14.1  36.7 
Sohn MH[1]  2008  Korea 
( Asian) 
218/93/15 174/66/13 0.050  0.19  52.1 94.6 
* The ref was referred to the reference numbers in this study. 
& data from the same source, so selected by the latest sample size. 
# NA: Not available. 
† Power was calculated by the DSTPLAN4.2 software with MAF in controls as the frequency of risk factor, OR was selected 1.5 and 2.0 as the 
relative risk and а=0.05 as the significance. 
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Table 2. Summary ORs of the RANTES -28C/G polymorphism and asthma risk. 
Comparison  No. of Cases  No. of Controls  OR  95%CI  P* 
CG vs CC  1833  1739  1.25   1.04-1.50  0.60  
GG vs CC  1538  1513  1.98   1.24-3.16  0.29  
GG vs CG+CC  1894  1766  1.88   1.18-3.00  0.30  
CG+GG vs CC  1894  1766  1.24   1.08-1.41  0.47  
* Test for heterogeneity. Fixed-effects model was used when P value for heterogeneity test > 0. 01; otherwise, random-effects model was 
used. 
Table 3. Association between asthma risk and the RANTES -28C/G polymorphisms, stratified by asthma type, age and 
ethnicity. 
Stratified variable  Studies of  
available$ 
No. of  
Cases 
No. of  
Controls 
OR# 95%CI  P* 
asthma type             
atopic [1,20]  577  495  1.04    0.75-1.44  0.81 
non-atopic [1,20]  200  495  1.15    0.69-1.90  0.61 
age            
children [1,13,15-17,19]  1229  1084  1.24    1.06-1.45  0.39 
adult [14,18,20]  665  682  1.24    0.96-1.60  0.29 
ethnicity            
Asian  [1,14-17]   1157  868  1.27   1.04-1.56  0.48 
Caucasian [13,20]  466  545  1.27    0.77-2.11  0.22 
African [18,19]  271  353  1.72  1.07-2.78  0.23 
# The OR was obtained in dominant genetic model. 
* Test for heterogeneity. Fixed-effects model was used when P value for heterogeneity test > 0.10; otherwise, random-effects model was used. 
$ Studies of available was referred to the reference resource of each stratified variable, which data was available. 
 
 
 
Figure 1. ORs (log scale) of asthma associated with RANTES -28C/G for the CG+GG genotypes, compared with the CC 
genotype. Int. J. Med. Sci. 2010, 7 
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Figure 2. Funnel plot analysis to detect publication bias in 
asthma. Each point represents a separate study for the 
indicated association. For each study, the OR is plotted on a 
logarithmic scale against the precision (the reciprocal of the 
SE). 
 
 
Discussion 
Regulated upon activation, normal T-cell ex-
pressed and secreted (RANTES) is a C-C chemokine 
that has been shown to be a potent chemoattractant 
for T cells, eosinophils, basophils, mono-
cyte/macrophages, and mast cells [22]. It has been 
shown that RANTES induces recruitment of eosino-
phils and their up regulation into the airways of 
asthmatic patients causing tissue damage [23-25]. 
Both atopic asthma and nonatopic asthma are associ-
ated with increased levels of RANTES in bronchoal-
veolar lavage fluid [26] and bronchial mucosal ex-
pression of RANTES (together with eosinophil-active 
cytokines such as interleukin-5, granulocyte macro-
phage colony-stimulating factor, and interleukin-3), 
which contributes to the bronchial mucosal accumu-
lation of activated eosinophils [27]. Mutations in the 
proximal promoter region of the RANTES gene may 
affect transcriptional activity and sub-sequently 
RANTES over expression in lung cells [19]. It was re-
ported that over expression of RANTES causes in-
creased neutrophils and eosinophils infiltration into 
the airways, which are considered a prominent fea-
ture of airway inflammation [28]. This inflammation 
is resulting mainly from recruitment of eosinophils in 
a manner that correlates with asthma severity [29]. 
Therefore, as one of the C-C chemokines, the 
RANTES polymorphisms necessarily resulted into the 
level of eosinophils elevating correspond, and then 
increased the individual risk of suffering from 
asthma. 
The expression of RANTES  is differentially 
regulated in various cell types, and a large number of 
putative cis-acting elements have been described in 
the promoter region by Nelson et al. [6], who subse-
quently also identified a novel regulatory region 
critical for its expression [30]. The RANTES -28C/G 
polymorphism was found to be adjacent to the NF-к
B binding site, which is a potent inducer of RANTES 
expression [31]. It has also been reported that the 
-28G allele elevates promoter activity and increase 
RANTES protein expression in the functional study 
[12]. In addition, Hizawa et al. [14] suggested that 
mononuclear cells from subjects who carried the -28G 
allele produced significantly greater levels of 
RANTES protein than cells from subjects who did not 
carry this allele. Thus, it is reasonable to hypothesize 
that the -28C/G polymorphism with higher activity 
of RANTES may play more important role in asthma 
risk. 
In the present meta-analysis on the association 
between RANTES -28C/G polymorphism and risk of 
asthma, we found that the variant -28G alleles could 
significantly increase the risk of asthma, which is 
consistent with the hypothesis from previous studies 
that the -28C/G polymorphism with higher activity 
of RANTES may be more important in asthma risk, 
although the association was not significantly evident 
in most studies individually. In addition, in stratified 
analysis, we observed that the association between 
-28C/G and risk of asthma was remained significant 
in Asian and African population. The different effect 
of ethnicity may result from several reasons such as: 
less numbers of available studies for stratified vari-
able, which may result into poor statistic power; dif-
ferent genetic background and environmental expo-
sures, which may contribute to ethnic difference. In 
addition, it is worth emphasizing that the -28C/G 
polymorphism was contributed to the increase of 
asthma susceptibility in children, which may helpful 
to understand the pathogenesis of children's asthma. 
Furthermore, small numbers of individuals and in-
consistent stratification standards in environmental 
exposures and genotypes by the published studies 
limited our statistic power to fully investigate the 
gene-environment interaction. 
In spite of this, our meta-analysis shares some Int. J. Med. Sci. 2010, 7 
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key advantages in several aspects. First, substantial 
number of cases and controls were pooled from dif-
ferent studies, which significantly increased statistical 
power of the analysis than each individual study. 
Second, the quality of case–control studies included 
in current meta-analysis was good and met our inclu-
sion criterion. Third, we did not detect any publica-
tion bias indicating that the whole pooled result 
should be unbiased. 
In conclusion, this meta-analysis of 9 
case-control studies provided evidence that the 
RANTES -28C/G polymorphism was significantly 
associated with increased risk of asthma, especially in 
children. Further well-designed large studies, par-
ticularly referring to gene-gene and 
gene-environment interactions are warranted to con-
firm the real contribution of RANTES -28C/G poly-
morphism to asthma susceptibility.   
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